Evidence map›Paper›PMID 40681475›Full record

ArticleClinical and translational medicine2025

YOD1 regulates oxidative damage of dopamine neurons in Parkinson's disease by deubiquitinating PKM2.

Xia Zhao, Jinfeng Sun, Fan Chen, Hao Tang, Yuqing Zeng, Luyao Li, Qin Yu, Linjie Chen, Muzaffar Hammad, Xiaoxia Xu and 3 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xia ZhaoAffiliated Yongkang First People's Hospital, Hangzhou Medical College, Yongkang, China.ORCID 0000-0002-7980-8592
Jinfeng SunKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji, China.
Fan ChenAffiliated Yongkang First People's Hospital, Hangzhou Medical College, Yongkang, China.
Hao TangSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
Yuqing ZengSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
Luyao LiChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Qin YuSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
Linjie ChenSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
Muzaffar HammadSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
Xiaoxia XuSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
Ziyao MengSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China.
Wei WangAffiliated Yongkang First People's Hospital, Hangzhou Medical College, Yongkang, China.
Guang LiangAffiliated Yongkang First People's Hospital, Hangzhou Medical College, Yongkang, China.ORCID 0000-0002-8278-849X

Funding

Medical and Health Science and Technology Project of Zhejiang Province 2025KY1032National Natural Science Foundation of China 21961142009National Natural Science Foundation of China 82360805Natural Science Foundation of Zhejiangprovince LTGY23H090001the Scientific Research Center, Hangzhou Medical CollegeZhejiang Provincial Key Scientific Project 2021C03041
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is a common neurodegenerative movement disorder, mainly characterized by the degeneration and loss of dopaminergic neurons in the substantia nigra. Oxidative stress is considered to be a key contributor to dopaminergic neuronal degeneration, triggering a series of downstream events such as mitochondrial dysfunction, neuroinflammation and misfolded protein aggregation, which ultimately exacerbate the development of PD. Deubiquitinating enzymes (DUBs) regulate oxidative stress, but their roles in PD remain unclear.

methodsGEO database analysis and western blotting were used to analyze the expression of YOD1in PD patients and PD mouse models. Genetic knockout (KO) of YOD1 was performed to assess its effects in PD pathogenesis. The substance of YOD1 was measured via co-immunoprecipitation (Co-IP) coupled with LC-MS/MS analysis. Then the effect of YOD1-mediated motor deficits and oxidative damage were investigated using open field test, swimming test, pole test, immunofluorescence (IF) and cellular analyses.

resultsYOD1 was highly expressed in PD patients and 6-OHDA-induced PD model mice and mediated reactive oxygen species (ROS) production. YOD1 KO ameliorated motor impairments and oxidative stress in PD model mice. YOD1 directly bound PKM2 and reduces its ubiquitination level by removing the K63-linked ubiquitin chain of PKM2, thereby increasing the tetramer level and reducing the dimer level of PKM2. It then inhibited dimerized PKM2 entry into the nucleus and regulated Nrf2-mediated antioxidant responses, but YOD1 does not change the stability of PKM2 protein.

conclusionsOur study identifies YOD1 as a oxidative-sensitive regulator of PD progression, operating via the YOD1-PKM2-Nrf2 axis. Targeting YOD1 may offer a novel therapeutic strategy for PD. KEY POINTS: YOD1 is highly elevated in different PD model mice and patients with PD. YOD1 is a key regulator in oxidative stress and PD pathology. YOD1-deficient exhibit a protective effect on neuronal oxidative injury. YOD1 targets PKM2-Nrf2 axis in response to oxidative stress.

Indexed as

Dopaminergic NeuronsMembrane ProteinsOxidative StressParkinson DiseaseAnimalsDisease Models, AnimalHumansMaleMiceMice, KnockoutPyruvate KinaseThyroid Hormone-Binding ProteinsMembrane ProteinsPkm protein, mousePyruvate KinaseThyroid Hormone-Binding Proteinsoxidative stressParkinson's diseasePKM2YOD1

Identifiers

PMID40681475
PMCPMC12274113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.